Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comparative Study of Carotid Ultrasound Findings in Patients With and Without Familial Hypercholesterolemia.

Cureus·2025
Same author

Safety and Effectiveness of Low-Density Lipoprotein Cholesterol-Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real-World, Postmarketing, Single-Arm Study.

Journal of the American Heart Association·2024
Same author

Fragility Fracture Network-Japan: The challenge of establishment of a national hip fracture database and successful achievement of nationwide health system change for hip fracture care in Japan.

Injury·2024
Same author

Understanding impacts of COVID-19 restrictions on glycemic control for patients with diabetes in Japan.

Journal of diabetes and metabolic disorders·2023
Same author

Effects of Nutrition Education Program for the Japan Diet on Serum Phospholipid Fatty Acid Compositions in Patients with Dyslipidemia: Re-analysis of Data from a Previous Randomized Controlled Trial.

Journal of atherosclerosis and thrombosis·2023
Same author

Apolipoprotein D modulates lipid mediators and osteopontin in an anti-inflammatory direction.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2022

Related Experiment Video

Updated: May 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pitavastatin: clinical effects from the LIVES Study.

Tamio Teramoto1

  • 1Department of Internal Medicine, Teikyo University School of Medicine, Kaga 2-11-1, Itabashi-ku, Tokyo 173-8605, Japan. ttera@med.teikyo-u.ac.jp

Atherosclerosis. Supplements
|December 14, 2011
PubMed
Summary

The LIVALO Effectiveness and Safety (LIVES) study found pitavastatin effectively lowers LDL cholesterol and improves HDL cholesterol in Japanese patients. Long-term use was well-tolerated, reducing cardiovascular risk, especially in those with low HDL-C.

Related Experiment Videos

Last Updated: May 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Clinical trial results for drug efficacy and safety may not always align with real-world patient outcomes.
  • Post-marketing surveillance is crucial for understanding long-term effectiveness and safety in diverse patient populations.
  • The LIVALO Effectiveness and Safety (LIVES) study was initiated to evaluate pitavastatin in a large Japanese cohort.

Purpose of the Study:

  • To assess the efficacy and safety of pitavastatin in routine clinical practice among approximately 20,000 Japanese patients.
  • To evaluate pitavastatin's impact on lipid profiles, including low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), and high-density lipoprotein-cholesterol (HDL-C).
  • To determine the achievement of lipid targets across different cardiovascular risk categories and identify predictors of cardiovascular risk.

Main Methods:

  • A prospective, long-term post-marketing surveillance study involving ~20,000 Japanese patients treated with pitavastatin.
  • Data collection included lipid levels (LDL-C, TG, HDL-C), achievement of Japan Atherosclerosis Society targets, and adverse events (AEs).
  • Subanalyses focused on HDL-C changes, effects in patients switching from other statins, and impacts on diabetes and chronic kidney disease.

Main Results:

  • Pitavastatin significantly reduced LDL-C by 29.1% within 104 weeks, with most reduction occurring within 4 weeks.
  • Significant improvements were observed in TG (-22.7%) and HDL-C (+19.9%) in patients with baseline lipid abnormalities.
  • High rates of LDL-C target attainment were observed across risk groups (50.3%-88.2%). Adverse events were infrequent (10.4%), mostly mild, with low discontinuation rates (7.4%).
  • Pitavastatin significantly increased HDL-C, particularly in patients with low baseline HDL-C, and showed sustained LDL-C reduction over 5 years.
  • On-treatment HDL-C and LDL-C levels were significant predictors of cardiovascular and cerebrovascular risk.

Conclusions:

  • Pitavastatin is well-tolerated and effective in managing lipid profiles in Japanese patients with hypercholesterolemia.
  • The drug demonstrates a notable ability to increase HDL-C levels, offering potential benefits for patients with low baseline HDL-C or those unresponsive to other statins.
  • Achieving both LDL-C and HDL-C targets with pitavastatin was associated with the greatest reduction in cardiovascular and cerebrovascular risk.